• Vaccine Name: rMV-TDV
• Target Pathogen: Dengue Virus
• Target Disease: Dengue Fever
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• Antigen: Bivalent fusion envelope protein domain III (ED3) of DENV-1,2,3,4 (Lin et al., 2020)
• E from Dengue virus 1 gene engineering:
  • Type: Recombinant vector construction
  • Description: domain 3 (Lin et al., 2020)
  • Detailed Gene Information: Click Here.
• E protein from Dengue Virus 2 gene engineering:
  • Type: Recombinant vector construction
  • Description: domain 3 (Lin et al., 2020)
  • Detailed Gene Information: Click Here.
• E from Dengue virus 3 gene engineering:
  • Type: Recombinant protein preparation
  • Description: domain 3 (Lin et al., 2020)
  • Detailed Gene Information: Click Here.
• E from Dengue virus 4 gene engineering:
  • Type: Recombinant vector construction
  • Description: domain 3 (Lin et al., 2020)
  • Detailed Gene Information: Click Here.
• Immunization Route: Intraperitoneal injection (i.p.)
• Description: rMV-TDV consists of two recombinant MV vectors carrying the genes encoding bivalent fusion envelope protein domain III (ED3) of DENV-1 and -3 or DENV-2 and -4. (Lin et al., 2020)

Mouse Response

• Vaccination Protocol: Groups of 6-8-week-old AG-hCD46 mice were immunized intraperitoneally with rMV-TDV, a mixture containing 1 × 10^5 pfu of rMV-D13 and 1 × 10^5 pfu of rMV-D24, or 2 × 10^5 pfu of rMV-EGFP for the control. Mice were boosted with the same recombinant viruses and doses four weeks later. (Lin et al., 2020)
• Immune Response: A significant ED3-specific IgG response was induced after a single injection of rMV-TDV, but it was not observed in rMV-EGFP-immunized mice, and the response reached peak titers after the boost and was maintained at a high level for at least 20 weeks. A significant increase in neutralizing antibody titers (NT) to the 4 DENV serotypes was observed in rMV-TDV-immunized mice 8 weeks after vaccination compared to the rMV-EGFP controls. Only rMV-TDV- but not rMV-EGFP-immunized mice showed an obvious increase in the ED3-specific IFN-γ response dominated by DENV-3 after a single injection. Even 5 or 20 weeks later, the significantly higher level of DENV-3-specific IFN-γ responses were still maintained in rMV-TDV-immunized mice compared to the rMV-EGFP group. DENV-specific IL-4 responses were almost undetectable even after the boost. (Lin et al., 2020)
• Challenge Protocol: Mice were challenged 4 weeks after the last immunization by subcutaneously injecting 1.5 × 107 ffu of wild-type DENV-2/16681. (Lin et al., 2020)
• Efficacy: . Consistent with the higher viremia and IFN-γ increase, TNF-α but not IL-6 or IL-10 was significantly increased in the peripheral blood cells of the rMV-EGFP controls at 3 days post challenge compared to those in rMV-TDV-immunized mice, which had no increase in inflammatory cytokines (p < 0.001). (Lin et al., 2020)
• Description: YAC-CD46 mice, which carry the MV receptor-human CD46 transgene, were crossbred into AG129 mice to obtain AG-hCD46 transgenic mice (B6.129-Ifnar−/−, Ifngr−/− Tg(CD46)). (Lin et al., 2020)